CanSino Biologics Inc. disclosed its movements in share capital for November 2025. The company’s total authorized share capital stood at RMB247,043,801 at the end of the reporting period, with no change in the number of authorized H shares, which remained at 132,670,900.

The authorized A shares decreased from 114,778,999 to 114,372,901. The issued H shares were unchanged at 132,670,900, while the issued A shares remained at 114,372,901 after the cancellation of 406,098 treasury shares. As of the end of the month, there were no remaining treasury shares.

Regarding share-based plans, an H Share Option Scheme approved on 23 October 2025 has 860,000 options outstanding under H shares. Additionally, a Restricted A Share Incentive Scheme granted 2,054,600 restricted shares on 27 October 2025 at RMB41.20 per share, with no new issuance or transfer of treasury shares reported in November 2025.